QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA

The CeTeG/NOA-09 trial demonstrated a significant survival benefit of radiotherapy with CCNU/temozolomide (TMZ) combination therapy compared to standard TMZ therapy as first-line treatment of O6-methylguanine-DNA methyltransferase (MGMT)-promotor hypermethylated glioblastoma. Quality of life (QoL) a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Weller, Johannes, Tzaridis, Theophilos, Steinbach, Joachim, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh, Bullinger, Lars, Galldiks, Norbert, Schaub, Christina, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Matthias, Schmid, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich, Schäfer, Niklas
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2018
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217495/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.906
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg